Cytokinetics Inc
NASDAQ:CYTK
Cytokinetics Inc
NASDAQ:CYTK
Price:
65.28 USD
0.35%
Market Closed
Updated:
May 8, 2024
Cytokinetics Inc
Cash from Financing Activities
|
Cytokinetics Inc
Cash from Financing Activities Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Cytokinetics Inc
NASDAQ:CYTK
|
Cash from Financing Activities
$221.3m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
76%
|
CAGR 10-Years
31%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Cash from Financing Activities
-$17.2B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-17%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash from Financing Activities
-$5.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash from Financing Activities
-$2.2B
|
CAGR 3-Years
31%
|
CAGR 5-Years
33%
|
CAGR 10-Years
N/A
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash from Financing Activities
-$562.2m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-51%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash from Financing Activities
-$1.4B
|
CAGR 3-Years
19%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Cytokinetics Inc's Cash from Financing Activities?
Cash from Financing Activities
221.3m
USD
221.3m
USD
Based on the financial report for Dec 31, 2023, Cytokinetics Inc's Cash from Financing Activities amounts to 221.3m USD.
What is Cytokinetics Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 10Y
31%
31%
Over the last year, the Cash from Financing Activities growth was -57%. The average annual Cash from Financing Activities growth rates for Cytokinetics Inc have been -2% over the past three years , 76% over the past five years , and 31% over the past ten years .
You don't have any saved screeners yet
